Table 2 The general pathologic characteristics of primary SCC/ASC patients and HCC patents
|  | Primary SCC/ASC group | HCC group | χ 2 /F/ t | P |
|---|---|---|---|---|
Patients | 9 | 40 | - | - |
Tumor capsule | Â | Â | Â | Â |
 Yes | 0 | 30(75%) | 14.392 | 0.000 |
 No | 9(100%) | 10(25%) | ||
Macrovascular invasion | Â | Â | Â | Â |
 Yes | 0 | 3(7.5%) | 0.006 | 0.937 |
 No | 9(100%) | 37(92.5%) | ||
Microvascular invasion | Â | Â | Â | Â |
 Yes | 2(22.2%) | 40 | 30.222 | 0.000 |
 No | 7(77.8%) | 0 | ||
Lymph node metastasis | Â | Â | Â | Â |
 Yes | 4(44.4%) | 7(17.5%) | 1.712 | 0.191 |
 No | 5(55.6%) | 33(82.5%) | ||
Histologic grade (Edmondson-Steiner) | Â | Â | 4.060 | 0.044 |
 I | 0 | 0 |  |  |
 II | 6(66.7%) | 10(25%) |  |  |
 III | 3(33.3%) | 30(75%) |  |  |